Yahoo · Oct 24, 2026
What Glaukos Doubters Missed
Investors who held Glaukos from the start of the year are up 61.6%, including dividends. That headline result lands next to a reminder that fresh Epioxa data, a new retinal licensing deal and record 2026 guidance all arrived only after the clock started. If you were deciding on 1 January whether to buy, what weight would you have put on early regulatory wins and high expected P/E multiples, compared with concentration and reimbursement risk? This theme extends beyond Glaukos. See which of 34...